Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cyclophosphamide conditioning for autologous HSCT in severe systemic sclerosis with cardiac or cardiopulmonary risk
ACTRN12617000216314Phase 2Active, not recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Dec 2016
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide and antithymocyte globulin in systemic sclerosis (SSc) (3 cohorts), sponsored by St Vincent's Hospital Sydney. Primary endpoints: Transplant-related mortality, Length of hospital stay and 1 more. Started Dec 2016; status: active, not recruiting.
02
Drugs
cyclophosphamideantithymocyte globulin
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ACTRN12617000216314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000216314.